Oliver J. McElvaney

Oliver J. McElvaney

Auto-generated profile, based on publicly available information

Oliver J. McElvaney

Royal Coll Surgeons Ireland, Dept Med, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
OMOliver J. McElvaney
Oliver J. McElvaney
NMNatalie L. McEvoy
Natalie L. McEvoy
OMOisín F. McElvaney
Oisín F. McElvaney
TCTomás P. Carroll
Tomás P. Carroll
MMMark P. Murphy
Mark P. Murphy
NMNoel G. McElvaney
Noel G. McElvaney
Rationale: Coronavirus disease (COVID-19) is a global threat to health. Its inflammatory characteristics are incompletely understood. Objectives: To define the cytokine profile of COVID-19 and to identify evidence of immunometabolic alterations in those with severe illness. Methods: Levels of IL-1β, IL-6, IL-8, IL-10, and sTNFR1 (soluble tumor necrosis factor receptor 1) were assessed in plasma from healthy volunteers, hospitalized but stable patients with COVID-19 (COVIDstable patients), patients with COVID-19 requiring ICU admission (COVIDICU patients), and patients with severe community-acquired pneumonia requiring ICU support (CAPICU patients). Immunometabolic markers were measured in circulating neutrophils from patients with severe COVID-19. The acute phase response of AAT (alpha-1 antitrypsin) to COVID-19 was also evaluated. Measurements and Main Results: IL-1β, IL-6, IL-8, and sTNFR1 were all increased in patients with COVID-19. COVIDICU patients could be clearly differentiated from COVIDstable patients, and demonstrated higher levels of IL-1β, IL-6, and sTNFR1 but lower IL-10 than CAPICU patients. COVID-19 neutrophils displayed altered immunometabolism, with increased cytosolic PKM2 (pyruvate kinase M2), phosphorylated PKM2, HIF-1α (hypoxia-inducible factor-1α), and lactate. The production and sialylation of AAT increased in COVID-19, but this antiinflammatory response was overwhelmed in severe illness, with the IL-6:AAT ratio markedly higher in patients requiring ICU admission (P < 0.0001). In critically unwell patients with COVID-19, increases in IL-6:AAT predicted prolonged ICU stay and mortality, whereas improvement in IL-6:AAT was associated with clinical resolution (P < 0.0001). Conclusions: The COVID-19 cytokinemia is distinct from that of other types of pneumonia, leading to organ failure and ICU need. Neutrophils undergo immunometabolic reprogramming in severe COVID-19 illness. Cytokine ratios may predict outcomes in this population.

1 November 2020 in EBioMedicine
Verified
Journal Article
Open access
OMOliver J McElvaney
Oliver J McElvaney
BHBrian D Hobbs
Brian D Hobbs
DQDandi Qiao
Dandi Qiao
OMOisín F McElvaney
Oisín F McElvaney
MMMatthew Moll
Matthew Moll
NMNoel G McElvaney
Noel G McElvaney
Prognostic tools are required to guide clinical decision-making in COVID-19. We studied the relationship between the ratio of interleukin (IL)-6 to IL-10 and clinical outcome in 80 patients hospitalized for COVID-19, and created a simple 5-point linear score predictor of clinical outcome, the Dublin-Boston score. Clinical outcome was analysed as a three-level ordinal variable (“Improved”, “Unchanged”, or “Declined”). For both IL-6:IL-10 ratio and IL-6 alone, we associated clinical outcome with a) baseline biomarker levels, b) change in biomarker level from day 0 to day 2, c) change in biomarker from day 0 to day 4, and d) slope of biomarker change throughout the study. The associations between ordinal clinical outcome and each of the different predictors were performed with proportional odds logistic regression. Associations were run both “unadjusted” and adjusted for age and sex. Nested cross-validation was used to identify the model for incorporation into the Dublin-Boston score. The 4-day change in IL-6:IL-10 ratio was chosen to derive the Dublin-Boston score. Each 1 point increase in the score was associated with a 5.6 times increased odds for a more severe outcome (OR 5.62, 95% CI -3.22–9.81, P = 1.2 × 10−9). Both the Dublin-Boston score and the 4-day change in IL-6:IL-10 significantly outperformed IL-6 alone in predicting clinical outcome at day 7. The Dublin-Boston score is easily calculated and can be applied to a spectrum of hospitalized COVID-19 patients. More informed prognosis could help determine when to escalate care, institute or remove mechanical ventilation, or drive considerations for therapies. Funding was received from the Elaine Galwey Research Fellowship, American Thoracic Society, National Institutes of Health and the Parker B Francis Research Opportunity Award.

1 December 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
OMOliver J. McElvaney
Oliver J. McElvaney
ZZZbigniew Zaslona
Zbigniew Zaslona
KBKatrin Becker-Flegler
Katrin Becker-Flegler
EPEva M. Palsson-McDermott
Eva M. Palsson-McDermott
FBFiona Boland
Fiona Boland
NMNoel G. McElvaney
Noel G. McElvaney
Rationale: Cystic fibrosis (CF) pulmonary disease is characterized by chronic infection with Pseudomonas aeruginosa and sustained neutrophil-dominant inflammation. The lack of effective antiinflammatory therapies for people with CF (PWCF) represents a significant challenge. Objectives: To identify altered immunometabolism in the CF neutrophil and investigate the feasibility of specific inhibition of the NLRP3 (NOD-, LRR-, and pyrin domain–containing protein 3) inflammasome as a CF antiinflammatory strategy in vivo. Methods: Key markers of increased aerobic glycolysis, known as a Warburg effect, including cytosolic PKM2 (pyruvate kinase M2), phosphorylated PKM2, succinate, HIF-1α (hypoxia-inducible factor-1α), lactate, and the IL-1β precursor pro–IL-1β, as well as caspase-1 activity and processing of pro–IL-1β to IL-1β by the NLRP3 inflammasome, were measured in neutrophils from blood and airway secretions from healthy control subjects (n = 12), PWCF (n = 16), and PWCF after double-lung transplantation (n = 6). The effects of specific inhibition of NLRP3 on airway inflammation and bacterial clearance in a murine CF model were subsequently assessed in vivo. Measurements and Main Results: CF neutrophils display increased aerobic glycolysis in the systemic circulation. This effect is driven by low-level endotoxemia, unaffected by CFTR (cystic fibrosis transmembrane conductance regulator) modulation, and resolves after transplant. The increased pro–IL-1β produced is processed to its mature active form in the LPS-rich CF lung by the NLRP3 inflammasome via caspase-1. Specific NLRP3 inhibition in vivo with MCC950 inhibited IL-1β in the lungs of CF mice (P < 0.0001), resulting in significantly reduced airway inflammation and improved Pseudomonas clearance (P < 0.0001). Conclusions: CF neutrophil immunometabolism is altered in response to inflammation. NLRP3 inflammasome inhibition may have an antiinflammatory and anti-infective role in CF.

9 April 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
OMOliver J. McElvaney
Oliver J. McElvaney
TCTomás P. Carroll
Tomás P. Carroll
AFAlessandro N. Franciosi
Alessandro N. Franciosi
JSJames Sweeney
James Sweeney
BHBrian D. Hobbs
Brian D. Hobbs
NMNoel G. McElvaney
Noel G. McElvaney
In Ireland, augmentation treatment of patients with genetic alpha1-antitrypsin deficiency was abruptly discontinued when government–industry price negotiations failed. After treatment was stopped, the incidence of hospitalization for COPD and mortality exceeded those observed while treatment was ongoing.

11 March 2022 in Med
Verified
Journal Article
Closed access
OMOliver J. McElvaney
Oliver J. McElvaney
NMNatalie L. McEvoy
Natalie L. McEvoy
FBFiona Boland
Fiona Boland
OMOisín F. McElvaney
Oisín F. McElvaney
GHGrace Hogan
Grace Hogan
GCGerard F. Curley
Gerard F. Curley

15 April 2019 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
EREmer Reeves
Emer Reeves
DDDanielle M. Dunlea
Danielle M. Dunlea
KMKaren McQuillan
Karen McQuillan
COCiara A O’dWyer
Ciara A O’dWyer
Tomás CarrollTomás Carroll
Tomás Carroll
NMNoel G. McElvaney
Noel G. McElvaney
Alpha-1 antitrypsin (AAT) is an acute phase protein that possesses immune-regulatory and anti-inflammatory functions independent of antiprotease activity. AAT deficiency (AATD) is associated with early-onset emphysema and chronic obstructive pulmonary disease. Of interest are the AATD nonsense mutations (termed null or Q0), the majority of which arise from premature termination codons in the mRNA coding region. We have recently demonstrated that plasma from an AATD patient homozygous for the Null Bolton allele (Q0bolton) contains AAT protein of truncated size. Although the potential to alleviate the phenotypic consequences of AATD by increasing levels of truncated protein holds therapeutic promise, protein functionality is key. The goal of this study was to evaluate the structural features and anti-inflammatory capacity of Q0bolton-AAT. A low-abundance, truncated AAT protein was confirmed in plasma of a Q0bolton-AATD patient and was secreted by patient-derived induced pluripotent stem cell–hepatic cells. Functional assays confirmed the ability of purified Q0bolton-AAT protein to bind neutrophil elastase and to inhibit protease activity. Q0bolton-AAT bound IL-8 and leukotriene B4, comparable to healthy control M-AAT, and significantly decreased leukotriene B4–induced neutrophil adhesion (p = 0.04). Through a mechanism involving increased mRNA stability (p = 0.007), ataluren treatment of HEK-293 significantly increased Q0bolton-AAT mRNA expression (p = 0.03) and Q0bolton-AAT truncated protein secretion (p = 0.04). Results support the rationale for treatment with pharmacological agents that augment levels of functional Q0bolton-AAT protein, thus offering a potential therapeutic option for AATD patients with rare mutations of similar theratype.